Drug Profile
Vonlerolizumab - Genentech
Alternative Names: MOXR-0916; Pogalizumab; RG 7888Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Genentech
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action OX40 ligand inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours; Urogenital cancer
Most Recent Events
- 22 Nov 2019 Genentech completes a phase-I trials in Solid tumours (Second-line therapy or greater, Combination therapy, Late-stage disease, Metastatic disease, Recurrent) in Spain, South Korea, France, Canada, Belgium, Australia, USA (IV) (NCT02410512)
- 30 May 2019 Discontinued - Phase-I for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) in Belgium, Canada, France, South Korea, Spain, Australia, USA (IV)
- 30 May 2019 Discontinued - Phase-I for Solid tumours (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA, Canada (IV) (NCT03029832)